Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer However, in either first-line or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback